BioCentury
ARTICLE | Finance

Maximizing depression

Euthymics spins out Neurovance; clears way for potential deal in depression

October 22, 2012 7:00 AM UTC

Euthymics Bioscience Inc. thinks spinning out its early stage assets into Neurovance Inc. will make it easier to partner Euthymics' lone remaining asset - its amitifadine candidate for depression.

The two companies will have the same management team, but will operate as independent entities. Euthymics will be responsible solely for amitifadine (formerly EB-1010), which is in the Phase II/III TRIADE trial for major depressive disorder. Data are expected in 1Q13...